Share

February 25, 2020; 94 (8) Article

Multiple cause of death analysis in multiple sclerosis

A population-based study

Katharine Harding, Feng Zhu, Mohammed Alotaibi, Thomas Duggan, Helen Tremlett, Elaine Kingwell
First published January 13, 2020, DOI: https://doi.org/10.1212/WNL.0000000000008907
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
241

Share

Article Information

vol. 94 no. 8 e820-e829
DOI: 
https://doi.org/10.1212/WNL.0000000000008907
PubMed: 
31932517
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received March 27, 2019
  • Accepted in final form August 8, 2019
  • First Published January 13, 2020.

Article Versions

Copyright & Usage: 
© 2020 American Academy of Neurology

Author Disclosures

    1. Katharine Harding, PhD,
    2. Feng Zhu, MSc,
    3. Mohammed Alotaibi, MD,
    4. Thomas Duggan, BSc,
    5. Helen Tremlett, PhD and
    6. Elaine Kingwell, PhD
  1. Katharine Harding, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Travel grant from Novartis UK to attend ECTRIMS 2018 in Berlin.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Honoraria from Biogen UK and Merck UK to speak at a meeting

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Feng Zhu, MSc,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Mohammed Alotaibi, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Thomas Duggan, BSc,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Helen Tremlett, PhD and
    6. Scientific Advisory Boards:

    1. All non-profit: • National US surveillance system for MS. 2013-2019. Invited by the US National MS Society to form an advisory group to enable the development of a national surveillance system capable of tracking the incidence and prevalence of MS. Monthly teleconferences; one face-to-face meeting: Atlanta, Georgia (March 2014) Status: Bipartisan legislation introduced to Congress - ‘Advancing Research for Neurological Diseases Act, H.R. 292.’to guide the Centers for Disease Control and Prevention in tracking the incidence and prevalence of neurological diseases, including Multiple Sclerosis and Parkinson’s disease [13th-Jan-2015; http://burgess.house.gov/blog/?postid=397459]

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Helen Tremlett is the Canada Research Chair for Neuroepidemiology and Multiple Sclerosis. Current research support received from the National Multiple Sclerosis Society, the Canadian Institutes of Health Research, the Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation. In addition, in the last five years, has received research support from the Multiple Sclerosis Society of Canada (Don Paty Career Development Award); the Michael Smith Foundation for Health Research (Scholar Award) and the UK MS Trust; speaker honoraria and/or travel expenses to attend CME conferences from the Consortium of MS Centres (2013, 2018), the National MS Society (2014, 2016, 2018), ECTRIMS (2013, 2014, 2015, 2016, 2017, 2018, 2019), Biogen Idec (2014), American Academy of Neurology (2013, 2014, 2015, 2016, 2019). All speaker honoraria are either declined or donated to an MS charity or to an unrestricted grant for use by HT’s research group.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Canada Foundation for Innovation (CFI); Canadian Institutes of Health Research [#363635 (co-PI); #190898 (PI); #404791; #387503; #388480 (all as PI); #MOP-82738 (PI) and MOP- 119393 (PI) and MOP-106607 (PI)]; the US National Multiple Sclerosis Society (Operating grants: 2012-15; 2014-17), the Multiple Sclerosis Society of Canada (2015-18: EGID #2624 (PI); 2016-18: EGID #2680 (co-PI); ) the The Multiple Sclerosis Scientific and Research Foundation (2015-18 (PI)); Canada Research Chair in Neuroepidemiology and Multiple Sclerosis

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Elaine Kingwell, PhD
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) MS Society of Canada (EGID 2624) Role: Study Lead (2015-2019) (2) MS Society of Canada (EGID 3221 ) Role: Study Lead (2018-2020) (3) Canadian Institutes of Health Research (CIHR) (#388480) Role: Co-investigator (2018-2022) (4) Canadian Institutes of Health Research (CIHR) (#159828) Role: Co-investigator/Project Lead (2018-2019)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Faculty of Medicine (Neurology) and Djavad Mowafaghian Centre for Brain Health (K.H., F.Z., T.D., H.T., E.K.), University of British Columbia, Vancouver, Canada; Department of Neurology (K.H.), Aneurin Bevan University Health Board, Royal Gwent Hospital, Newport, UK; and Department of Ophthalmology (M.A.), King Saud University, Riyadh, Saudi Arabia.
  1. Correspondence
    Dr. Kingwell elainejk{at}mail.ubc.ca
View Full Text

Article usage

Article usage: January 2020 to April 2022

AbstractFullPdfSource
Jan 2020512024Highwire
Feb 20204164232Highwire
Mar 202017536140Highwire
Apr 202023112615Highwire
May 2020115138Highwire
Jun 20209352Highwire
Jul 202010091Highwire
Aug 20209323Highwire
Sep 202013785Highwire
Oct 20208253Highwire
Nov 202010943Highwire
Dec 202015031Highwire
Jan 202112234Highwire
Feb 2021152210Highwire
Mar 202118529Highwire
Apr 202121918Highwire
May 202116634Highwire
Jun 202121365Highwire
Jul 202121952Highwire
Aug 202123402Highwire
Sep 202122475Highwire
Oct 202124625Highwire
Nov 20212461110Highwire
Dec 202129530Highwire
Jan 2022288214Highwire
Feb 2022239313Highwire
Mar 202244911Highwire
Apr 2022449512Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me